|
|
|
Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets CS1, a cell surface glycoprotein highly expressed on myeloma cells but minimally expressed on normal cells. Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.
|
|
|
|
|
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab
to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma. The Eloquent Trial fact sheets are also available in German, French, Italian, Spanish, and Dutch. |
|
|
|
|
Phase III Randomized, Open-label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma |
|
|
back
print
back to top